ReviewCornea2019
Sjögren's Syndrome: More Than Just Dry Eye.
Review in Cornea, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 2 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology (Oxford, England) · 2025Guideline
- Management of corneal perforations in dry eye disease: Preferred practice pattern guidelines.Indian journal of ophthalmology · 2023Guideline
- A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren's syndrome.Rheumatology (Oxford, England) · 2023Trial
- Characteristics of Tear Film in Sjögren's Syndrome Patients as Measured by a Novel Tear Film Imager: A Pilot Study.Journal of clinical medicine · 2026Article
- Comparative Utility of Tear Film and Ocular Surface Parameters in Differentiating Sjögren's Disease Dry Eye From Non-Sjögren's Dry Eye.Translational vision science & technology · 2026Article
- Bridging Therapeutics and Nanotechnology in Dry Eye Disease: A Review of Risk Factors, Drug Delivery Barriers, and Recent and Future Endeavors for Disease Management.AAPS PharmSciTech · 2026Review
- Nanomaterial-enabled smart contact lenses: bridging sensing, therapy, and theranostics for next-generation ocular healthcare.Journal of nanobiotechnology · 2026Review
- Sjogren's Disease-Aspects of Clinical Disease Beyond Dry Eyes/Mouth.Journal of clinical medicine · 2026Review
- Unveiling dry eye with autoimmune features (DEAF): insights from a prospective longitudinal study.Clinical rheumatology · 2026Article
- Practical Guide to the Local Treatment of Sjogren's Disease.Journal of clinical medicine · 2026Review
- Patient-Reported Symptoms Versus Clinician-Measured Signs to Distinguish Sjogren's in Patients With Dry Eye.Translational vision science & technology · 2026Article
- Muscle relaxant use and the associated risk of Sjögren's syndrome and dry eye disease (including keratoconjunctivitis sicca) in patients with ankylosing spondylitis: a population-based cohort study.Therapeutic advances in drug safety · 2026Article
- Hydrogels in Autoimmune Disease: A Comprehensive Review of Current Research and Clinical Potentials.International journal of nanomedicine · 2026Review
- Sutureless Amniotic Membrane Grafting in the Management of Corneal Perforations Associated with Severe Ocular Surface Disease.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Dry Eye Syndrome as a Potential Sequel of Laryngopharyngeal Reflux: Shared Mechanisms and Clinical Implications.Maedica · 2025Review
- Symptom-based stratification of heterogeneous symptoms of dry eye disease in patients with Sjögren's syndrome.Eye (London, England) · 2025Article
- The relation between corneal optical quality and clinical ocular surface manifestations in Chinese female with Sjogren's syndrome dry eye.BMC ophthalmology · 2025Article
- A population-based study on association of iridocyclitis with Sjogren's syndrome.Eye (London, England) · 2025Article
- Correlation among ocular surface changes and systemic hematologic indexes and disease activity in primary Sjögren's syndrome: a cross-sectional study.BMC ophthalmology · 2025Article
- Evaluating the efficacy of stem cells in treating severe dry eye disease.World journal of stem cells · 2025Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purposeSjögren's syndrome (SS) is a common autoimmune disease affecting about four million Americans. Although approximately 1 in 10 patients with clinically-significant aqueous deficient dry eye has underlying SS, widespread underappreciation of SS leads to significant underdiagnosis, delays in diagnosis, and consequent morbidity and mortality. The purpose of this article is to illustrate that in addition to dry eye, SS can cause serious, vision-threatening extraglandular ocular manifestations.
methodsWe conducted a narrative review of studies that have examined the dry eye and extraglandular ocular complications of SS.
resultsSS-related dry eye is a progressive condition with major negative impact on the quality-of-life of afflicted patients, not only due to symptoms of ocular discomfort but also visual dysfunction. In addition, SS can lead to corneal melt/perforation, uveitis, scleritis, retinal vasculitis, and optic neuritis. A major problem with currently-available SS disease activity measurement instruments is the lack of domains evaluating dry eye-related visual dysfunction. For example, one of the most commonly-used instruments for assessing patient symptoms in SS (the EULAR Sjögren's Syndrome Patient Reported Index [ESSPRI]) only includes one item (out of three) that addresses the severity of overall dryness, without mention of dry eye symptoms or vision-related quality-of-life. Similarly, no extraglandular ocular complications are included in currently-available SS disease activity instruments (e.g., the EULAR Sjögren's Syndrome Disease Activity Index [ESSDAI]).
conclusionsThere needs to be a paradigm shift in which eye care providers and rheumatologists become more familiar with various SS-related extraglandular ocular manifestations. Existing disease activity measurement instruments must incorporate dry eye symptoms, particularly those related to visual dysfunction. An evidence-based screening algorithm for determining which patients with dry eye should be tested for underlying SS may be particularly helpful in preventing delays in diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.